The webinar will be broadcasting on Wednesday, December 6 at 10am CST (Chicago) and 5pm CET (Paris) and will last for 60 minutes. There will be an opportunity to submit questions throughout.
We have three extremely knowledgeable and forward-looking members on the panel including Dawn Anderson from Deloitte Life Sciences & Healthcare who is managing director of the company’s life sciences, research, and development. She is extremely knowledgeable about the industry and will be joining us to speak about patient diversity and will lightly touch upon patient retention.
Part of her presentation will look across the clinical trial ecosystem where there are barriers to clinical trial participation which primarily include trust, access, and awareness. She will also be looking at diversity strategies that must be prioritized when designing clinical trials to cultivate a proactive patient-centric approach.
Also appearing is Steve O’Keeffe, a serial entrepreneur who has joined the non-profit sector founding Angry@Arthritis. His aim is to raise awareness and money to find new cures for osteoarthritis (OA).
He said he started the organization to ‘challenge the failing status quo’ and to provide a patent-centric resource for people who get an OA diagnosis.
He said on his site: “Born out of this frustration, I created Angry@Arthritis to cut through the pain. In addition to providing patients with better, more actionable information – and hope – we’re focused on raising the public profile of this terrible disease and on crowdsourcing funding to support new OA cures.
“There’s a gaping hole between the research and clinical solutions. Let’s raise money together to fund a fix for OA.”
During the webinar, he will talk about the biggest frustrations for clinical research patients, and how the clinical research industry can make improvements. He will also talk to us about his experience of lobbying Congress for more OA funding.
We are also delighted to have Steve Rosenburg who is CEO of uMotif, an eCOA/ePRO platform provider whose roots are in putting patients at the heart of their own management of long-term health conditions.
Listening to talks at conferences or conducting interviews during them, the patient is always mentioned as a priority, no matter what the sector - and with the constant evolvement of, and shift towards, patient-centric healthcare, the pharma industry must keep up.
Patient centricity is a key focus because ultimately it is they, the patients, who are contributing to advancements in medicine that could save lives.
Patient-centricity should emphasize the importance of considering the patient’s experience with a particular treatment. Pharmaceutical companies can come up with interventions and support programs that improve patient consent and compliance which in turn can lead to better outcomes and improved overall patient experience and satisfaction.
As you can see, there is plenty to discuss and share, and we really hope we have enticed you to join - it should be an interesting and lively webinar, not to mention informative and thought-provoking.
To join, click here.